Basile Njei, MD, PhD, MPH, FACHDM
Assistant ProfessorCards
About
Research
Publications
2025
The Role of Artificial Intelligence Combined With Digital Cholangioscopy for Indeterminant and Malignant Biliary Strictures: A Systematic Review and Meta-analysis.
McCarty TR, Shah R, Allencherril RP, Moon N, Njei B. The Role of Artificial Intelligence Combined With Digital Cholangioscopy for Indeterminant and Malignant Biliary Strictures: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2025 PMID: 39998988, DOI: 10.1097/MCG.0000000000002148.Peer-Reviewed Original ResearchMortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study.
Njei B, Mezzacappa C, John BV, Serper M, Kaplan DE, Taddei TH, Mahmud N. Mortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study. Dig Dis Sci 2025 PMID: 39779587, DOI: 10.1007/s10620-024-08764-4.Peer-Reviewed Original ResearchLiver Fibrosis and Cardiovascular Events.
Nso N, Bookani KR, Trimingham M, Orji R, Njei B, Balasubramanian SS, Pursnani A. Liver Fibrosis and Cardiovascular Events. South Med J 2025, 118: 19-25. PMID: 39753232, DOI: 10.14423/SMJ.0000000000001769.Peer-Reviewed Original Research
2024
Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status
Re V, Newcomb C, Carbonari D, Mezochow A, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Torgersen J. Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status. Pharmacoepidemiology And Drug Safety 2024, 33: e70069. PMID: 39662972, PMCID: PMC11634562, DOI: 10.1002/pds.70069.Peer-Reviewed Original ResearchConceptsProton pump inhibitor initiationHazard ratioVeterans Health AdministrationSevere acute liver injuryProton pump inhibitorsChronic liver diseaseAcute liver injuryRates of hospitalizationSafety of medicationsPPI initiativesHealth AdministrationLiver disease statusMedication exposurePharmacoepidemiological studiesMedicationConfoundingScoresReports of hepatotoxicityDisease statusHepatotoxic medicationsDrug exposurePump inhibitorsHepatotoxic drugsOutpatient initiationHepatic safetyThe impact of overweight and obesity on health outcomes in the United States from 1990 to 2021.
Al Ta'ani O, Al-Ajlouni YA, Aleyadeh W, Al-Bitar F, Alsakarneh S, Saadeh A, Alhuneafat L, Njei B. The impact of overweight and obesity on health outcomes in the United States from 1990 to 2021. Diabetes Obes Metab 2024, 26: 5455-5465. PMID: 39261301, DOI: 10.1111/dom.15924.Peer-Reviewed Original ResearchThe burden of cirrhosis and other chronic liver disease in the middle east and North Africa (MENA) region over three decades.
Al Ta'ani O, Aleyadeh W, Al-Ajlouni Y, Alnimer L, Ismail A, Natour B, Njei B. The burden of cirrhosis and other chronic liver disease in the middle east and North Africa (MENA) region over three decades. BMC Public Health 2024, 24: 2979. PMID: 39468483, DOI: 10.1186/s12889-024-20445-5.Peer-Reviewed Original ResearchDiagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review.
Njei B, Ameyaw P, Al-Ajlouni Y, Njei LP, Boateng S. Diagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review. Cureus 2024, 16: e71451. PMID: 39544615, DOI: 10.7759/cureus.71451.Peer-Reviewed Original ResearchEfficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Njei B, Al-Ajlouni Y, Lemos SY, Ugwendum D, Ameyaw P, Njei LP, Boateng S. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus 2024, 16: e71366. PMID: 39534801, DOI: 10.7759/cureus.71366.Peer-Reviewed Original ResearchRecipient functional status impacts on short and long-term intestinal transplant outcomes in United States adults.
Boateng S, Ameyaw P, Gyabaah S, Adjepong Y, Njei B. Recipient functional status impacts on short and long-term intestinal transplant outcomes in United States adults. World J Transplant 2024, 14: 93561. PMID: 39295973, DOI: 10.5500/wjt.v14.i3.93561.Peer-Reviewed Original ResearchSevere Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data
Torgersen J, Mezochow A, Newcomb C, Carbonari D, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Re V. Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data. JAMA Internal Medicine 2024, 184: 943-952. PMID: 38913369, PMCID: PMC11197444, DOI: 10.1001/jamainternmed.2024.1836.Peer-Reviewed Original ResearchIncidence rateUS Department of Veterans AffairsMedication initiationDepartment of Veterans AffairsInitiation of medicationVeterans AffairsMain OutcomesPotential of medicationsOutpatient settingDischarge diagnosisCohort studyDay of admissionCase reportReal World DataReport countsMedicationMedical cohortSevere acute liver injuryUS DepartmentFollow-upAcute liver injuryHospitalCohortHepatotoxic medicationsIncidence
Academic Achievements & Community Involvement
News
News
- March 06, 2025
Meet Yale Internal Medicine: Basile Njei, MD, PhD, MPH
- December 03, 2024Source: MEDPAGETODAY
Lean MASH Patients Face Higher Mortality and Worse Outcomes
- October 27, 2024Source: HCPLive American College of Gastroenterology
Basile Njei, MD, MPH, PhD: Increasing Lean MASLD Awareness, Improving Screening
- October 04, 2024
Voices of DEI: Basile Njei, MD, MPH, PhD
Get In Touch
Contacts
Email
Academic Office Number
Mailing Address
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520
United States
Locations
950 Campbell Avenue
Academic Office
VA Connecticut Healthcare
Wing Building 35A, Fl 2, Rm 210
West Haven, CT 06516